Moderna, Inc. MRNA
At closeNov 11, 2026, 4:43 PM EST
After hours · Nov 11, 4:43 PM ET
- YTD
- +743.30%
- 1 year
- +841.65%
- Market cap
- 100.63B
- Revenue (ttm)
- 2.52B
- Profit margin
- -110.45%
- EPS (ttm)
- -7.04
- Shares out
- 404.62M
- Forward P/E
- -59.29
- YTD return
- +743.30%
- 1-year return
- +841.65%
- Volume
- 7.54M
- Avg volume
- 22.00M
- Open
- 252.78
- Previous close
- 250.83
- Day's range
- 243.00 – 254.86
- 52-week range
- 22.28 – 280.80
- Beta
- 1.17
- Analysts
- Hold
- Price target
- 158.47 (-36.3%)
- Earnings date
- Feb 12, 2027
5D -5.74 (-2.26%)
Key statistics
- Enterprise value
- 100.55B
- PEG ratio
- 0.00
- Price / sales
- 39.85
- Price / book
- 14.70
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 29.20%
- Free cash flow
- -584.50M
- Total cash
- 5.17B
- Total debt
- 4.23B
- Return on equity
- -34.50%
- Short % of float
- 9.99%
- 50-day average
- 196.68
- 200-day average
- 93.58
Analyst view
Consensus: hold
- Target (low)
- 45.00
- Target (mean)
- 158.47
- Target (high)
- 305.00
- Strong buy1
- Buy3
- Hold16
- Sell2
- Strong sell1
Next earnings
Feb 12, 2027
Expected Feb 12, 2027. Consensus EPS estimate -2.16.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 12, 2027 | Dec 30, 2026 | -1.73 | — | — | — |
| Nov 6, 2026 | Sep 30, 2026 | -1.10 | 0.38 | +1.48 | +134.55% |
| Jul 31, 2026 | Jun 30, 2026 | -2.03 | -1.97 | +0.06 | +2.96% |
| May 1, 2026 | Mar 31, 2026 | -4.45 | -3.40 | +1.05 | +23.60% |
| Feb 13, 2026 | Dec 31, 2025 | -2.54 | -2.11 | +0.43 | +16.93% |
| Nov 6, 2025 | Sep 30, 2025 | -1.87 | -0.51 | +1.36 | +72.73% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | Goldman Sachs | main | Neutral | Neutral |
| Nov 9, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Oct 27, 2026 | William Blair | down | Outperform | Market Perform |
| Oct 26, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Oct 21, 2026 | TD Cowen | main | Hold | Hold |
| Oct 15, 2026 | Goldman Sachs | main | Neutral | Neutral |
About Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- modernatx.com
News
Moderna Highlights JAMA Publication Of Real-World Comparative Effectiveness Data For COVID-19 Vaccine Adults Aged 65 Years and Older
Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy
Can Moderna's First Cancer Therapy Win FDA Approval in 2027? Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $195
Piper Sandler Reiterates Overweight on Moderna, Raises Price Target to $305
Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain?
Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology
BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era.
Moderna: 3 Key Takeaways for Long-Term Investors
Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell?
Your note
Sign in to keep a note on MRNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AFEYAN NOUBAR BOGHOS | Director | Sale | May 20, 2026 | 0 |
| BANCEL STEPHANE J | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 5, 2026 | 22,215,800 |
| HOGE STEPHEN | President | Conversion of Exercise of derivative security | Sep 14, 2026 | 1,718,080 |
| HORNING SANDRA | Director | Conversion of Exercise of derivative security | Apr 29, 2026 | 18,585 |
| HUSSAIN SHAH ABBAS | Director | Sale | Apr 30, 2026 | 12,066 |
| KLINGER SHANNON THYME | Officer | Conversion of Exercise of derivative security | Sep 3, 2026 | 81,340 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.57% | 58,955,948 | 14.66B | Sep 29, 2026 |
| Blackrock Inc. | 7.56% | 30,599,409 | 7.61B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 5.74% | 23,208,792 | 5.77B | Jun 29, 2026 |
| Capital World Investors | 5.51% | 22,276,996 | 5.54B | Jun 29, 2026 |
| State Street Corporation | 3.89% | 15,726,193 | 3.91B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.85% | 15,581,313 | 3.87B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Growth Fund of America | 3.70% | 14,983,229 | 3.73B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.80% | 11,331,692 | 2.82B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.26% | 9,154,510 | 2.28B | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.09% | 8,471,575 | 2.11B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.02% | 8,190,072 | 2.04B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.28% | 5,187,970 | 1.29B | Jun 29, 2026 |
